skip to main content
Idioma:
Primo Search
Clear Search Box
Search in: Busca Geral
Busca Avançada
Busca por Índices

Inflammatory and autoimmune predictive markers of response to anti‑PD‑1/PD‑L1 therapy in NSCLC and melanoma

Musaelyan, Aram A ; Lapin, Sergey V ; Urtenova, Margarita A ; Odintsova, Svetlana V ; Chistyakov, Ivan V ; Ulitin, Andrey M ; Akopov, Andrey L ; Orlov, Sergey V

Experimental and therapeutic medicine, 2022-09, Vol.24 (3), Article 557

Athens: Spandidos Publications

Texto completo disponível

Citações Citado por
  • Título:
    Inflammatory and autoimmune predictive markers of response to anti‑PD‑1/PD‑L1 therapy in NSCLC and melanoma
  • Autor: Musaelyan, Aram A ; Lapin, Sergey V ; Urtenova, Margarita A ; Odintsova, Svetlana V ; Chistyakov, Ivan V ; Ulitin, Andrey M ; Akopov, Andrey L ; Orlov, Sergey V
  • Assuntos: Antibodies ; Biological markers ; Biomarkers ; Cancer ; Cancer therapies ; Care and treatment ; Chemotherapy ; Cloning ; Cytokines ; Disease ; Dosage and administration ; Drug therapy ; Health aspects ; Immune response ; Immunology ; Immunotherapy ; Lung cancer ; Lung cancer, Non-small cell ; Melanoma ; Metastasis ; Methods ; Monoclonal antibodies ; Patients ; Physiological aspects ; Receptor antibodies ; Test systems ; Thyroid gland ; Tumors
  • É parte de: Experimental and therapeutic medicine, 2022-09, Vol.24 (3), Article 557
  • Notas: Professor Sergey V. Orlov, Department of Clinical Oncology, Pavlov First Saint Petersburg State Medical University, 6-8 L'va Tolstogo St., Saint Petersburg 197022, Russia orloff-sv@mail.ru
  • Descrição: Immune checkpoint inhibitors (ICI) are a standard in cancer therapy, but few patients respond to the treatment. The aim of the present study was the determination of immunological markers for monitoring response to ICI. The present study included 74 patients receiving ICI in subsequent [group 1; non-small cell lung cancer (NSCLC)] and first-line setting (group 2; melanoma) and 30 patients with NSCLC receiving first-line chemotherapy. In groups 1 and 2 [beta]-2 microglobulin (B2-MG), neopterin (NPT), IL-6, IL-18, HLA-DRB1 and autoantibodies were assessed after two months of ICI, and before the start of next administration in group 3. In group 1 low level of B2-MG (P<0.0001), NPT (P<0.0001), IL-6 (P<0.0001), IL-18 (P=0.0003), HLA-DRB1*03 (P=0.016) and anti-TPO antibodies (P=0.016) were associated with response >six months. In group 2 high level of B2-MG (P=0.0001), NPT (P=0.0016), IL-6 (P=0.013) and IL-18 (P=0.032) were associated with early disease progression (<six months). Univariate analysis demonstrated that immune-related adverse events were predictive marker of prolonged progression-free survival (PFS) in group 1 (P=0.038) and 2 (P=0.020). Neutrophil-lymphocyte ratio [greater than or equal to] 5 before immunotherapy was correlated with shorter PFS in melanoma in multivariate analysis (P=0.007). B2-MG [greater than or equal to] 2.5 mg/ml (P=0.006) and NPT >12 nmol/l (P=0.027) were predictors of shorter PFS in group 1. B2-MG [greater than or equal to] 2.5 mg/ml was predictor of shorter PFS (P=0.008) in group 2. In group 1 levels of B2-MG, NPT, IL-6 and IL-18 were higher than in group 3. In summary, immunological markers are promising predictive markers for immunotherapy; however, it requires further prospective studies. Key words: immune checkpoint inhibitors, immune-related adverse events, autoantibodies, HLA-DRB1, neutrophil-to-lymphocyte ratio, peripheral blood biomarker, [beta]-2 microglobulin, neopterin, interleukin-6, interleukin-18
  • Editor: Athens: Spandidos Publications
  • Idioma: Inglês
Voltar para lista de resultados
Ir para página anteriorAnterior Resultado  6 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.